Business Wire

TOM FORD Announces Appointment of Haider Ackermann as Creative Director

4.9.2024 15:30:00 CEST | Business Wire | Press release

Share

TOM FORD announces the appointment of Haider Ackermann as Creative Director, effective immediately.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240904332237/en/

Haider Ackermann appointed Creative Director, TOM FORD. (Photo Credit: Ethan James Green)

In his new role, Ackermann will assume the creative leadership across all TOM FORD fashion categories, including menswear, womenswear, accessories, and eyewear, and guide the creative vision for the overall brand. TOM FORD is owned by The Estée Lauder Companies Inc. (NYSE:EL) with the fashion business licensed to the Ermenegildo Zegna Group (NYSE:ZGN) and the eyewear business licensed to Marcolin SpA.

Founder Tom Ford said, “I have long been a great fan of Haider’s work. I find both his womenswear and menswear equally compelling. He is an incredible colorist, his tailoring is sharp, and above all he is modern. We share many of the same historical references, and I could not be more excited to see what he does with the brand. I suspect that I will be the first on my feet to applaud after his show in March.”

A French national born in Bogotá, Colombia, Ackermann's upbringing spanned Ethiopia, Chad, Algeria, The Netherlands, and Belgium, where he studied fashion at the Royal Academy of Fine Arts in Antwerp. Known for blending luxurious fabrics with impeccable tailoring, Ackermann has garnered acclaim for his avant-garde, yet wearable designs favored by celebrities.

“It is with tremendous pride that I will seek to honor the legacy of Tom Ford, a man I have long admired and have the utmost respect for,” said Ackermann. “I am much looking forward to what lies ahead.”

Ackermann's first collection will debut at Paris Fashion Week in March 2025. He will be based in Paris, reporting to Guillaume Jesel, President and CEO, TOM FORD and Luxury Business Development, The Estée Lauder Companies, and to Lelio Gavazza, CEO, TOM FORD FASHION, Ermenegildo Zegna Group.

“Haider stands out as one of the world's most visionary and inspiring talents in fashion. He draws on his deep affinity for global culture and the arts to create arresting fashion and memorable emotional connections. He is the ideal steward to usher TOM FORD into the future," said Jesel.

“I am extremely pleased to welcome Haider as Creative Director of TOM FORD. His unparalleled creativity, which is aligned with the brand's DNA, as well as his renowned experience in luxury will be instrumental in driving the fashion business forward during its next important phase of expansion. Working alongside the talented team at TOM FORD FASHION, Haider’s modern vision, for both men’s and women’s wear, will be essential as we advance and execute the many projects we have in development,” said Gavazza.

About TOM FORD

TOM FORD is a global design house offering exceptional luxury products across women’s and men’s fashion, accessories, eyewear and beauty. Founded in 2005 by Tom Ford, the brand has a presence in more than 100 markets globally and is widely recognized as the architect of luxury glamour. In 2023, The Estée Lauder Companies became the sole owner of the TOM FORD brand and all its intellectual property. In connection with the acquisition, The Estée Lauder Companies established long term licenses with Ermenegildo Zegna Group for TOM FORD FASHION and Marcolin for TOM FORD EYEWEAR.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240904332237/en/

Contacts

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Takeda Receives U.S. FDA Approval of MIMRYLO™ (rusfertide), Marking a Potential Shift in the Treatment Paradigm for Polycythemia Vera29.8.2026 00:40:00 CEST | Press release

MIMRYLO, a First-in-Class Medicine with a Unique Mechanism of Action, is Approved for the Treatment of Erythrocytosis in Adults with Polycythemia Vera (PV)MIMRYLO Has Been Shown to Maintain Hematocrit Control, the Primary Treatment Goal in PV, as Well as Reduce Phlebotomy Burden and Improve FatigueApproval Supported by Phase 3 VERIFY Results Showing 76.9% of Patients Achieved Clinical Response During Weeks 20-32 Takeda (TSE:4502/NYSE:TAK)announced U.S. Food and Drug Administration (FDA) approval of the New Drug Application (NDA)* for MIMRYLO™ (rusfertide) for the treatment of erythrocytosis in adults with polycythemia vera (PV), a blood cancer. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260824773270/en/ MIMRYLO Logo MIMRYLO is a first-in-class hepcidin mimetic designed to regulate iron distribution in the body and red blood cell overproduction to control hematocrit levels, which is the ratio of red blood cells to the tot

Rigaku and Tohoku University Establish a New Research Institute for X-Ray Metrology28.8.2026 16:00:00 CEST | Press release

Rigaku Corporation, a group company of Rigaku Holdings and a global solutions partner for X-ray analytical systems (Head Office: Akishima, Tokyo; President and CEO: Jun Kawakami; “Rigaku”), and Tohoku University (Sendai, Miyagi; President: Teiji Tominaga; “Tohoku University”) have established the Rigaku-Tohoku University Co-Creation Research Institute for X-ray Metrology: Beyond The Limits (the “Institute”) at Tohoku University on August 1, 2026. The Institute will advance X-ray metrology technology, develop new metrology methods, and foster the next generation of researchers through an initial three-year collaboration, with the possibility of extension based on its achievements. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828688510/en/ Inside the Institute As semiconductors become smaller, more multilayered, and incorporate a wider range of materials, manufacturing processes are becoming increasingly complex. X-ray me

BLK: Portfolio Company of Enry’s Island S.p.A., Lists on Euronext Dublin28.8.2026 15:34:00 CEST | Press release

Enry’s Island S.p.A. (WBAG:EIOS), an international venture builder with headquarters in the Tremiti Islands and the Metaverse, announces that BLK Global PLC, one of the portfolio companies within its ecosystem, has successfully completed its admission to trading on Euronext Access Dublin. Trading in the company’s shares commenced on Friday, July 31, 2026, under ticker BLKX and ISIN GB00BPSKS130. BLK was one of the thousands of applications received by Enry’s Island which, following an assessment process based on the Enry’s Model, was selected for a one-year incubation and acceleration programme. The programme supported the company through its subsequent growth stages, ultimately leading to its current stock market listing. Alessandro Pacciana, Investor Relations Manager of Enry’s Island S.p.A., said: “BLK’s listing is the second stock market listing in two years among Enry’s Island’s portfolio companies, while Enry’s Island itself is the world’s first listed venture builder. We are pro

Zambon Announces European Commission Approval of Hopledo® for Adults with Parkinson's Disease and Moderate to Severe Motor Fluctuations28.8.2026 11:00:00 CEST | Press release

Hopledo® is a first-in-class, oral, modified-release formulation of levodopa/carbidopa (LD/CD) approved for the treatment of motor fluctuations of Parkinson’s disease Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026 The approval is based on data from the Phase 3 RISE-PD trial where Hopledo® demonstrated a significant increase in Good ON time compared with immediate-release LD/CD with fewer daily doses and a comparable safety profile Zambon today announced that the European Commission (EC) has granted marketing authorization for Hopledo® (modified-release levodopa/carbidopa) for the treatment of adult patients with Parkinson’s disease and moderate to severe motor fluctuations who have not been sufficiently stabilized with oral levodopa/dopa decarboxylase (DDC) inhibitor-based treatment regimens. Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026. The company is working closely

MTG-I2 Safely in Orbit, Unlocking Faster and Sharper Weather Monitoring Across Europe28.8.2026 10:16:00 CEST | Press release

The Meteosat Third Generation Imager 2 satellite (MTG-I2) has successfully passed its first critical post-launch milestones, completing the first full Meteosat Third Generation constellation in orbit. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828243790/en/ Credit: Arianespace livestream The imager satellite MTG-I2 is safely in orbit and operating as expected following its successful launch yesterday at 22:11 CEST on board an Ariane 6 rocket from Europe’s Spaceport in French Guiana. Our teams have established communication with the spacecraft, which has also deployed its solar panels to ensure its autonomous production of energy. MTG-I2 is in perfect shape to start its Launch and Early Operations Phase that will bring it to a higher orbit, 36 000km above Earth over the following two weeks, where a longer period of calibration and validation of its instruments will begin. This summer’s extreme weather and wildfires hav

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye